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ABSTRACT
Treatment of fungal eye infections represents a challenge to the ophthalmology practice. For an adequate therapeutic response,
besides correct drug choice, it is necessary an effectively administration. This script gathers information about the major antifungal
drugs used in eye infections, their concentrations and main administration routes.
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RESUMO
O tratamento das infecções oculares por fungos representa um desafio à prática oftalmológica. Para obtermos resposta tera-
pêutica adequada, além do uso da droga correta, é necessária a administração desta de forma eficaz. Este manuscrito reúne infor-
mações a respeito das principais drogas antifúngicas utilizadas em infecções oculares, suas concentrações e principais vias de admi-
nistração.
Descritores: Antimicóticos/uso terapêutico; Infecções oculares fúngicas; Micoses; Leveduras; Fungos filamentosos
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INTRODUCTION
Fungal eye infections are important causes of ocular mor-bidity. Since the first report of a fungal keratitis by Leber-in 1879(1), an increasing number of cases has been ob-
served. Factors such as corticosteroid use, which facilitates the
penetration of pathogens, and the popularisation of topical anti-
biotics, which create an environment of lower competition among
microorganisms on the ocular surface, as suggested as key fac-
tors for such increase.
Despite the emergence of new drugs, cure remains diffi-
cult in many cases. Compared to antibacterials, antifungals have
a lower efficacy due to their mechanism of action (usually fungi-
static, with fungicidal action being dose dependent), lower tissue
penetration, and the indolent nature of the infection(4).
This paper aims to present information on the main anti-
fungals currently used for the treatment of fungal keratitis and
endophthalmitis, highlighting their advantages and disadvantages
in order to facilitate the choice of the most appropriate therapy
for each case.
POLYENES
This class of antifungal agents includes amphotericin B
(AMB), nystatin and natamycin (NTM). Nystatin has not been
used to treat eye infections for several decades due to its low
tissue penetration, toxicity, and reports of resistance(5,6). How-
ever, AMB and NTM remain as the primary drugs in the treat-
ment of fungal eye infections.
- Amphotericin B
AMB belongs to the family of polyene macrolide antibiot-
ics and was the first broad-spectrum antifungal agent to be dis-
covered. Isolated in the 1950s, AMB is produced by the actino-
mycete Streptomyces nodosus. It became popular after approval
by the FDA in the 1960s due to its great efficiency in controlling
disseminated fungal infections(4,6-8). In ophthalmology, it is still
the reference drug.
AMB acts by increasing cell permeability through the for-
mation of pores or channels in the fungal cell membrane upon
binding to ergosterol and by promoting oxidative action on cells,
thus altering their metabolic functions. It also binds to choles-
terol in human cells, which is the main reason for its side effects(8,9).
The drug’s name is derived from its amphoteric properties
(soluble in extreme pHs, both acidic and basic). It has low water
solubility and needs to be diluted in deoxycholate for adminis-
tration. AMB has long molecules that, when infused, coalesce
into a colloid. It is photo- and thermosensitive and should be stored
in a dark and refrigerated place (2-8°C)(4,6,7,10). Its action is pri-
marily fungistatic, with fungicidal action depending on the con-
centration reached in the target tissue(11).
In internal medicine, its use is limited due to its toxicity
and side effects. During infusion, fever, chills, hyperventilation,
hypotension, nausea, and vomiting may occur, among others. It
always causes tubular injury with loss of kidney function in pa-
tients with previous kidney disease. It is also partly eliminated
by the liver(8,11,12). AMB should not be diluted in saline solution,
as aggregation of colloids can occur, thus reducing the drug’s
bioavailability.
AMB acts on both yeasts and filamentous fungi. It has an
excellent spectrum, being effective against Candida spp., Aspergil-
lus spp., Penicillium marneffei, Criptococus spp. and the causative
agents of mucormycosis. It is also effective, to a lesser extent, against
the main Fusarium species. It has no antibacterial activity(4).
AMB also promotes immunopotentiation by binding to
cholesterol on the cell membrane of lymphocytes. Suppressor T
lymphocytes have higher concentrations of cholesterol in their
cell membrane than B and T helper lymphocytes, therefore AMB
leads to a reduction in suppressor cells with a relative increase
in pro-inflammatory cells(13,14).
Systemic administration of AMB produces little penetra-
tion into ocular tissues and does not reach therapeutic levels in
the cornea, aqueous or vitreous humour(4,10,15-17). Furthermore,
its side effects discourage systemic administration. Direct in situ
administration is therefore the main form of treatment. It is one
of the few drugs described in the literature as being used through
the subconjunctival, intrastromal, intracameral, and intravitreal
routes, as well as topically.
Topical administration in concentrations of 1.5 to 5 mg/ml
is commonly the first choice in the treatment of fungal keratitis.
The product has to be prepared from the intravenous formula-
tion (Fungizone™ - Bristol-Meyers Squibb, New York, NY) di-
luted in distilled water. It is used at hourly intervals at the begin-
ning of treatment, and then every 4 hours after the therapeutic
response is observed. Periodic debridement of the corneal epi-
thelium is recommended during treatment, because the
molecule’s large size hinders penetration into the cornea if the
epithelium is intact. After topical administration of AMB in rab-
bits whose corneal epithelium had been removed, therapeutic
levels were reached in the corneal stroma. However, in corneas
with intact epithelium, concentrations were low or undetectable(18-
21). The drug showed good tolerability and efficiency when used
both as eye drops and ointment(22,23).
Subconjunctival administration can be used in patients with
low adherence to treatment, but it is limited due to reports of
conjunctival necrosis, scleritis and scleral thinning(24,25).
Intracorneal administration, on the other hand, provides
better results. There are few reports of complications with this
route of administration; also, it provides higher and more sus-
tained corneal concentrations than topical or intracameral ad-
ministration. Several cases of keratitis unresponsive to topical
treatment are successfully resolved after intrastromal adminis-
tration(18,26), but further controlled studies are still needed. In-
trastromal administration of AMB at a concentration of 5 to 10
ìg is suggested for deep infections affecting the stroma that do
not respond well to topical treatment(2). The interval between
doses should be at least seven days and the drug should be ad-
ministered under peribulbar block, as it causes intense pain.
Doses above 15 to 20 ì g can cause endothelial cell loss and per-
sistent corneal oedema(18).
Intracameral injection can also be used at a concentration
of 5 to 10 ì g/0.1ml. It is administered at least once daily, due to the
rapid removal of the drug, without significant endothelial loss. It is
indicated in deep infections that penetrate Descemet’s membrane
and affect the anterior chamber and/or the lens. There are reports
of cataract after administration and of a transient increase in cham-
ber reaction within 24 hours due to the immunopotentiating effect
of AMB. Other side effects such as iritis and corneal oedema may
occur, but they are reversible(27-31).
For the treatment of fungal endophthalmitis, intravitreal
injection of AMB is the therapy of choice. The recommended
dose ranges from 1 to 10 ì g/0.1ml and may be repeated weekly.
In vitrectomised patients, the dosing regimen should be reduced
to every 3 or 4 days(32). Clinical and experimental studies dem-
onstrate the safety and efficacy of this route of administration;
however, there are reports of toxicity and retinal necrosis, which
are probably dose dependent(3,33).
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In eye infections caused by yeasts (especially Candida
spp.), AMB is still the drug of choice. Although therapeutic suc-
cess depends on using the drug for a long period (at least 4 weeks),
there are few reports of drug resistance by these organisms(34).
Among filamentous fungi, especially Fusarium spp., there are
reports of drug resistance(3,10).
- Natamycin
Similar to AMB, natamycin (NTM) or pimaricin is a poly-
ene antifungal used only in the treatment of fungal keratitis. It is
also used as a pesticide and as a preservative in the food indus-
try (3,35).
NTM has a long molecule with low water solubility. Pre-
sented as a suspension, it needs to be shaken before administra-
tion. It is the only drug approved by the Food and Drug Admin-
istration (FDA) for the treatment of fungal keratitis. In some
countries, the drug is commercially available (Natacyn™, Alcon
Laboratories, Fort Worth, TX). In Brazil, it needs to be com-
pounded(3,10).
Used at a concentration of 5% (50 mg/ml), it had good
stability and is well tolerated when used topically. Due to its high
molecular weight, NTM has low corneal penetration and is only
indicated as a monotherapy in the treatment of superficial infec-
tions(10,36). In deep infections or those involving intraocular struc-
tures, NTM should be associated with other antifungal agents
using a different route of administration(2,37-39).
Due to its low corneal penetration, therapeutic success
requires long term use of the drug, averaging 39 days(37). Epi-
thelial debridement is recommended as an adjuvant therapy so
that higher concentrations can be achieved in the corneal stroma.
This provides a greater adherence of the drug to the de-epithelised
surface (3,40). However, in a study by Prajna et al. epithelial scrap-
ing did not improve healing time. In fact, in this study epithelial
scraping was associated with lower visual acuity after healing(41).
The dosing interval is similar to AMB, and can be increased
once symptoms improve. Some infections require sustained treat-
ment for longer periods; doses every 4 hours maintain therapeu-
tic concentrations in the cornea with good long-term tolerabil-
ity(42).
Subconjunctival administration is discouraged due to seri-
ous complications, such as scleritis and conjunctival necrosis(3,24,43).
There are no reports of administration of NTM through other
routes (intracameral, intravitreal, intrastromal, or systemic).
NTM is a broad-spectrum agent, especially against fila-
mentous fungi. Although NTM can also be used in yeast infec-
tions, AMB remains the drug of choice due to its wider spectrum
against Candida species(39,44).
Fusarium infections are usually treated successfully with
NTM, especially superficial infections(45,46). Lalitha et al., in a
comparative study on the minimum inhibitory concentrations
(MIC) of different antifungal agents, reported that NTM has a
lower relative MIC than AMB both against Fusarium and As-
pergillus species(47). In another clinical trial comparing the effi-
cacy of NTM versus voriconazole (VCZ), no difference was
found between the two groups in terms of healing time and final
visual acuity (41). Kalavathy et al. compared the efficacy of NTM
and fluconazole (FCZ) and found better results in the group
treated with NTM, although the difference was not significant(45).
Several other studies also highlighted the superiority of NTM in
the treatment of infections by Fusarium spp.(48-50). Nevertheless,
certain authors have shown that about one third of Fusarium
infections do not respond to NTM(37,51,52). In such cases, NTM
should be replaced by or associated with another drug.
AZOLES
Introduced into medical practice in the 1970s, azoles rep-
resented an important advance in antifungal therapy. Compared
to AMB, they have a broader spectrum of action and cause fewer
adverse effects. Their use spread rapidly, especially in the treat-
ment of infections of the skin and mucous membranes(8).
Azoles act on fungal cytochrome P450 enzymes by block-
ing the synthesis of ergosterol in the plasma membrane, thus in-
hibiting fungal growth. Azoles are divided into two major classes
— imidazoles were the first to be introduced, followed by triazoles.
Both have similar antifungal spectra, but triazoles have the ad-
vantages of being metabolised more slowly and exerting less in-
fluence on the metabolism of steroids in humans(4,8). These drugs
are metabolised primarily in the liver, therefore control of liver
enzymes is recommended. They have teratogenic activity (class
C) and should not be used during pregnancy(4,53).
The imidazoles used more often in ophthalmology include
miconazole (MCZ), econazole (ECZ) and ketoconazole (KCZ).
Among the first-generation triazoles, the most used are
itraconazole (ICZ) and fluconazole. Second-generation triazoles
were introduced into clinical practice in the past decade and in-
clude voriconazole and posaconazole (PCZ).
- Miconazole
MCZ has been developed for use as a topical cream to
treat diseases of the skin and mucous membranes and is used
primarily in the treatment of superficial mycoses. It is effective
against several strains of Candida, being used primarily in the
treatment of dermatophitosis and oral and vaginal candidiasis,
due to its rapid fungicidal action(54). Systemic administration pro-
duces good results but is in disuse due to its cardiovascular and
hepatotoxic side effects(55,56).
MCZ not only acts on the synthesis of ergosterol, similar
to other azoles, but also promotes the inhibition of peroxidases,
resulting in an accumulation of free radicals in the fungal cyto-
plasm which leads to cell death(57-60).
Topical use at a concentration of 10 mg/ml has good pen-
etration, particularly if associated with epithelial scraping(61-63).
Topical MCZ was also effective in an experimental study where
therapeutic concentrations were maintained even with less fre-
quent dosing(64). It is notably effective and safe when used sub-
conjunctivally (1.2 to 10 mg) in the treatment of infections caused
by Candida, Fusarium, Curvalaria, and Aspergillus(2,61,65,66). Sys-
temic use does not reach therapeutic corneal concentrations and
is discouraged due to its adverse effects(61,67).
Compared to polyenes, MCZ is less effective but provides
better penetration into ocular tissues(5,61). In vitro, it was more
effective than KCZ and ICZ against Aspergillus spp., Candida
albicans and non-albicans(50,68). Further comparative controlled
studies are needed to demonstrate the real benefits of this drug.
- Econazole
ECZ, an imidazole with a similar molecular structure to
MCZ, is used primarily in the treatment of superficial mycoses,
with some studies involving systemic use(69).
It has been little studied in the treatment of eye infections,
but there are some reports of topical administration to treat fun-
gal keratitis. In a controlled clinical trial comparing eye drops of
ECZ 2% (20 mg/ml) with NTM 5%, there was no statistical dif-
ference between the rates of therapeutic success in the two
groups; both groups had with good results with no reports of ad-
verse reactions(42). Mahashabde et al. suggest the use of ECZ
ointment 1% as prophylactic treatment after ocular trauma with
risk of fungal infection(70). Unfortunately, the drug is not com-
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mercially available for ophthalmic administration, which prevents
its use.
- Ketoconazole
KCZ was the first systemic imidazole to be used success-
fully, but its use is now uncommon in internal medicine. It has
been replaced by ICZ due to the latter’s milder influence on the
metabolism of glucocorticoids and extended antifungal spec-
trum(4). It is used at a dose of 100 to 400 mg every 12 hours; its
oral absorption depends on gastric pH (below 3), therefore it
should be taken without food or gastric acid-suppressive agents.
It can be associated with gastric intolerance, hepatotoxicity, gy-
necomastia, and menstrual changes(8,10).
Although its penetration into the cerebrospinal fluid and
urine is low, its penetration into ocular tissues is significant when
used systemically. There are numerous reports of therapeutic
success with oral KCZ with or without topical NTM or AMB in
the treatment of fungal keratitis. Some authors suggest its rou-
tine use in all cases of fungal keratitis(71-73), but this is not sup-
ported by controlled studies.
There are reports of cases treated exclusively with topical
KCZ (10 to 50 mg/ml)(74), but other drugs have been shown to
be superior in comparative studies. Komadina et al. and Singh et
al., comparing topical and oral KCZ with NTM, showed that the
latter is superior. A partial response was also achieved with iso-
lated oral administration, with increased effect when combined
with topical NTM(75,76).
In vitro studies with strains of Aspergillus spp. and Fusarium
spp. exhibited a lower susceptibility of these organisms to KCZ
compared to NTM and VCZ(50). Other laboratory studies also
showed similar results with strains of Aspergillus, Fusarium and
Candida spp., which were susceptible to KCZ only at high
doses(34,77).
Currently, systemic KCZ is indicated only for the adjuvant
treatment of deep fungal keratitis.
- Itraconazole
ICZ is more frequently used in general practice than KCZ
and has fewer side effects when administered systemically. How-
ever, when administered orally it exhibits lower bioavailability,
solubility and penetration into ocular tissues than other
azoles(3,10,78,79). Similar to KCZ, gastric absorption depends on a
low pH. Studies in rats showed that ICZ has a lower teratogenic
risk than KCZ(53).
Systemic administration at 400 mg/day was effective in the
treatment of infections by Candida spp.(80). However, in infec-
tions by Fusarium spp., some studies suggest that ICZ is ineffec-
tive. Topical use at a concentration of 10 mg/ml was not as effec-
tive as NTM 5%(45). In vitro studies found that ICZ had a higher
MIC than AMB and NTM(48,78), and even found some drug resis-
tance among all analysed strains(47). ICZ was effective against
Aspergillus spp., but not as effective as KCZ(77).
Systemic use should be limited only to the adjuvant treat-
ment of eye infections by yeasts.
- Fluconazole
Unlike ICZ and KCZ, FCZ shows excellent absorption from
the gastrointestinal tract and is not influenced by gastric acidity.
Its plasma concentrations with oral use reach almost the same
levels as with intravenous administration. Penetration into ocu-
lar tissues is effective, reaching aqueous concentrations similar
to those in the plasma(4,81).
Oral use at 200 to 400 mg per day was effective in the
treatment of eye infections, with or without topical NTM(82,83).
When used subconjunctivally in association with topical AMB, a
broader antifungal spectrum was observed with less toxicity than
isolated AMB(84). Yilmaz and Maden managed to treat 60% of
cases of fungal keratitis with subconjunctival injections of FCZ
alone(85). A subconjunctival dose of 2 mg in 1 ml administered
daily for 10 days is recommended, followed by every 48 hours
until remission(86).
FCZ eye drops achieved good intracorneal therapeutic
levels against strains of Aspergillus fumigatus in rabbits. Used at
a concentration of 2 mg/ml, its penetration was better after epi-
thelial scraping(87,88).
FCZ is less effective than other drugs in the treatment of
fungal endophthalmitis. Despite its good vitreal penetration when
administered orally, its ineffectiveness against filamentous fungi
discourage its use as an adjuvant. However, there are reports of
successful treatment of endogenous endophthalmitis by Candida
spp. with FCZ(89-91).
Even though its ocular penetration is superior to KCZ, in
vitro and in vivo studies showed that the antifungal spectrum of
FCZ is narrower. In several studies that evaluated the suscepti-
bility of causative agents of fungal keratitis and endophthalmitis,
only Candida species were susceptible to FCZ, and filamentous
fungi (Aspergillus and Fusarium spp.) exhibited marked resis-
tance(34,48,77,92).
- Voriconazole
VCZ has the same mechanism of action than first-genera-
tion triazoles, but is more effective in blocking the synthesis of
ergosterol. VCZ was developed from the FCZ molecule and pre-
sents better efficacy at lower MICs than the first triazoles, which
increases its effectiveness against filamentous fungi(8). Because
of its great efficacy in treating disseminated fungal infections,
with lower toxicity compared to AMB, VCZ is currently the drug
of choice in the treatment of invasive aspergillosis(93).
VCZ is commercially available for oral and parenteral
administration (Vfend™ - Pfizer, New York, NY). It is
metabolised by the liver, therefore liver enzymes should be con-
trolled during therapy. Among its side effects are visual disor-
ders (blurred vision, change in colour perception and photopho-
bia), which are present in about 30% of patients using the drug
and are usually reversible. Similar to FCZ, it presents good gas-
tric absorption and bioavailability(4,92).
Administered orally at a dose of 200 mg every 12 hours,
VCZ reaches peak plasma concentrations after 2-3 hours. The
drug has been extensively studied in the treatment of keratitis
and endophthalmitis due to its good concentrations in several
ocular tissues (cornea, vitreous and aqueous)(32,94). Hariprasad
et al. found concentrations of VCZ in the vitreous and aqueous
humours corresponding to 38% and 51% of plasma levels, re-
spectively, after oral administration. Although the concentrations
achieved in the vitreous were insufficient to treat infections by
Fusarium spp., the authors argue that the study was conducted in
non-inflamed eyes, and that in the presence of inflammation a
more permeable blood-ocular barrier would help increase the
local concentrations of the drug(95). Alfonso et al. suggest VCZ
as the drug of choice for oral use in the treatment of deep kerati-
tis, scleritis, and endophthalmitis and as prophylaxis after pen-
etrating keratoplasty(2). Hariprasad et al. also suggest oral VCZ
as prophylaxis in cases of ocular trauma with plant material(92).
Intravitreal administration was shown to be safe in an ex-
perimental model with rats, with no changes in electroretinogra-
phy in doses up to 25mg/ml(96).
There are also numerous reports of therapeutic success
with topical VCZ. Administered at a concentration of 1 mg/ml, it
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was effective in the treatment of keratitis by Candida, Aspergil-
lus, Fusarium, Scedosporium, and Paecilomyces, among others(97-
101). Its advantages compared to polyenes include its greater sta-
bility to light and temperature, remaining effective for up to 30
days(102,103). Studies in horses showed drug penetration even with
epithelial integrity(104).
Some reports support the use of intracorneal VCZ in cases
of deep keratitis unresponsive to topical and/or oral administra-
tion. Prakash et al. report success in three cases of keratitis unre-
sponsive to topical NTM using VCZ 50 ìg/0.1 ml(105). Recently
Siatiri et al. described 3 cases of Fusarium keratitis unresponsive
to topical treatment that resolved after intracorneal VCZ(106). The
authors suggest that direct injection of VCZ in the cornea increases
its concentration above its minimum inhibitory concentration for
Fusarium species. Sharma et al., in a series with 13 patients, also
suggest the use of intrastromal VCZ in refractory keratitis(107).
However, there are few studies comparing VCZ with other
antifungal agents. In a multicenter randomised study VCZ was
not found to be superior to NTM, with both groups having simi-
lar healing times and final visual acuity(41). There are even re-
ports of treatment failure with VCZ. Giaconi et al. reported two
cases, a keratitis by Fusarium oxysporum and another by
Colletotrichum dematium, which were unresponsive to topical
therapy with VCZ(108).
In vitro studies demonstrate the superiority of VCZ to
AMB against Aspergillus spp.(109-112). Against Fusarium species,
the absolute MIC of VCZ, NTM and AMB were similar, with
VCZ having a lower relative MIC than the polyenes(47). Even
so, the minimum inhibitory concentration of VCZ for Fusarium
species was superior to Candida and Aspergillus species(77).
- Posaconazole
Similar to VCZ, PCZ is a second-generation triazole recently
introduced into medical practice. It results from an improvement
in the molecule of ICZ and is primarily indicated for the treat-
ment of invasive fungal infections in onco-hematological patients.
It is only available as an oral solution (Noxafil™ - Schering-Plough,
Kenilworth, NJ) and should be administered at a dose of 200 mg
four times daily or 400 mg twice daily. A parenteral presentation
is currently being developed. Gastrointestinal complaints are the
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Table 1
Antifungal agents and their indications
Drug Route of Dosing Indication
administration
Amphotericin B Topical 1.5-5mg/ml - First choice in the treatment of keratitis by yeasts
- Alternative to NTM in the treatment of keratitis by filamentous fungi
Intrastromal 5-10µg - Deep keratitis with partial response to topical treatment
Intracameral 5-10µg/0.1ml - Keratitis affecting the internal chamber and/or lens
Intravitreal 1-10µg/0.1ml - First choice in the treatment of fungal endophthalmitis (by yeasts or
filamentous fungi)
Natamycin Topical 50mg/ml - First choice in the treatment of fungal keratitis by filamentous fungi
- Alternative to AMB in the treatment of keratitis by yeasts
Miconazole Subconjunctival 1.2-10mg/1ml - Associated with topical therapy in patients with low adherence to
treatment
Econazole Topical 20mg/ml - Alternative to NTM in keratitis by filamentous fungi
Ketoconazole Oral 100-400mg - Associated with topical therapy in deep keratitis or those affecting
 every 12h  intraocular tissues
Itraconazole Oral 400mg/day - Associated with topical therapy in deep keratitis by yeasts or those
affecting intraocular tissues
Fluconazole Topical 2mg/ml - Alternative to polyenes in the treatment of fungal keratitis
Subconjunctival 2mg/1ml - Associated with topical therapy in patients with low adherence to
treatment
Oral 200-400mg/day - Associated with topical therapy in deep keratitis or those affecting
intraocular tissues
Voriconazole Topical 1mg/ml - Fungal keratitis resistant to polyenes and first-line triazoles
Intrastromal 50µg/0,1ml - Deep keratitis with partial response to topical drugs or in patients
with low adherence to treatment
Intracameral 50µg/0,1ml - Fungal keratitis affecting the internal chamber and/or lens
Intravitreal 50µg/0,1ml - Alternative to AMB in fungal endophthalmitis
Oral 200mg every 12h - Associated with topical therapy in deep keratitis or those affecting
intraocular tissues- Prophylaxis after eye trauma with plant material
Posaconazole Topical 100mg/ml - Fungal keratitis resistant to polyenes and first-line triazoles
Oral 200mg every 6h or - Adjunctive therapy in deep keratitis and endophthalmitis by
400mg every 12h organisms resistant to polyenes and first-line triazoles.
Flucytosine Topical 10mg/ml - Associated with topical AMB in fungal keratitis by yeasts
Caspofungin Topical 1.5-5mg/ml - Fungal keratitis by yeasts resistant to polyenes and first-line triazoles
Micafungin Topical 1mg/ml - Fungal keratitis by yeasts resistant to polyenes and first-line triazoles
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only adverse effects reported to date(113).
In vitro and in vivo studies show that PCZ has a broad spec-
trum against Candida spp., Cryptococcus neoformans, Aspergillus
spp., and Fusarium spp., among others. PCZ was effective against
most agents resistant to ICZ and FCZ(114,115) and, together with
VCZ, had the lowest MIC against multiple agents(47).
Experience with its use in ocular infections is still limited,
but initial results are encouraging. In a series of three cases of
Fusarium keratitis progressing to endophthalmitis unresponsive
to treatment with oral and topical VCZ, a rapid therapeutic re-
sponse to PCZ was observed(36). Sponsel et al. also describe a
case of keratitis by Fusarium solani resistant to AMB and NTM
but successfully treated with oral PCZ 200 mg 4 times daily as-
sociated with topical use (100 mg/ml prepared from an oral solu-
tion)(116). However, comparative controlled studies with first-line
antifungal agents are still lacking.
PYRIMIDINES
Pyrimidines are represented by 5-fluorocytosine (5-FC) or
flucytosine, which is the only antifungal agent with intracellular
action. After being absorbed by the fungus it is converted into 5-
fluorouracil, a powerful antimetabolic which acts by inhibiting
the synthesis of DNA(4,117).
Its use in eye infections is restricted due to its narrow
antifungal spectrum and low penetration into ocular tis-
sues(17). It is effective against Candida spp., with varied ac-
tion against Aspergillus spp. It is ineffective against Fusarium
spp. Systemic or topical administration should be associated
with AMB, primarily due to its potentiating effect (syner-
gism) and because of induction of resistance when 5FC is
used alone(4,6,77,118).
ECHINOCANDINS
Echinocandins are semisynthetic lipopeptides that inhibit
the synthesis of glucan in the fungal cell wall through non-com-
petitive inhibition of the enzyme 1,3-â-glucan synthase, causing
osmotic imbalance and cell lysis(8,119,120). This class of drugs in-
cludes caspofungin (CFG) and micafungin (MFG).
Used in yeast infections, echinocandins have rapid fungi-
cidal action against most Candida species, including strains re-
sistant to FCZ, but not against Cryptococcus, Rhodotorula and
Trichosporon(121). Echinocandins have fungistatic action against
some filamentous fungi such as Aspergillus, but not against
Fusarium and Rhizopus(47,122). CFG is administered intravenously
(Cancidas™ - Merck & Co - Whitehouse Station, NJ) at a dose
of 70 mg on the first day and 50 mg on the following days(4,8).
MFG (Mycamine™ - Astellas Ireland - Killorglin, Ireland) is also
administered intravenously at a dose of 100 to 150 mg/day.
Topical CFG at a concentration 1.5 to 5 mg/ml was as ef-
fective as AMB in the treatment of corneal ulcer by Candida
albicans in an animal model(123). Two other studies involving topical
MFG 1 mg/ml found an efficacy comparable or superior to FCZ
in the treatment of keratitis by Candida albicans and Candida
parapsilosis(124,125).
ASSOCIATION OF ANTIFUNGAL AGENTS
In order to increase treatment efficiency or even broaden
the antifungal spectrum, drugs are commonly associated in the
treatment of eye infections. Although some combinations of an-
tifungals such as 5-FC and AMB are widely used(126), other less
studied associations may not be as effective as expected.
Azoles are often associated with standard topical antifun-
gal agents such as NTM or AMB. However, several studies
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showed an antagonistic effect between these drugs. The intro-
duction of an azole decreases the synthesis of ergosterol in the
cell membrane, a binding site for polyenes, whose action is there-
fore decreased.
Arora et al. observed this antagonistic effect between ECZ
and AMB in the treatment of fungal keratitis, whose association
produced therapeutic results similar to ECZ alone(127). In a re-
view article, Sugar et al. showed an in vitro antagonistic effect
between AMB and various azoles (MCZ, KCZ, FCZ and ICZ),
with decreased polyene action(128). In a similar study, Li et al.
found an antagonistic effect between NTM+ICZ and NTM+FCZ
and a synergistic effect between AMB+ICZ(48).
Studies in humans and animals usually do not reproduce
these laboratory findings. There are countless reports of improve-
ment with the association of antifungal agents, especially when
topical AMB is associated with first- and second-generation sys-
temic triazoles(129,130). This combination should be used in deep
corneal infections or those with intraocular involvement.
The combination of two drugs of the same class is discour-
aged (e.g. NTM+AMB) because it increases local toxicity and
also fails to increase therapeutic efficacy(131).
OTHER DRUGS
Alternatives to antifungal agents have been studied to treat
keratitis of unclear aetiology. In a number of cases, povidone-
iodine 2.3% was used successfully to treat keratitis by Candida
albicans and Acremonium strictum(132). However, in a compara-
tive study, povidone-iodine 0.5% showed no benefit compared
to NTM 5% in the treatment of experimental keratitis by
Fusarium solani(40). In another experimental study, Fiscella et al.
showed that polyhexamethylene biguanide (PHBM) 0.02% is
effective in the treatment of eye infections by Fusarium solani in
rabbits(133). However, there are no comparative studies between
PHMB and antifungal agents.
Experimental trials involving topical corticosteroids asso-
ciated with antifungal therapy found deleterious effects. O’Day
et al. showed a modified host response after the introduction of
corticosteroids. In their study, in rabbits infected with Candida
albicans, Aspergillus fumigatus and Fusarium solani that received
subconjunctival corticosteroids corneal sterilisation occurred later
than in the control group(134). Weiyun et al. studied the risk fac-
tors for recurrence of the fungal infection after transplantation
and found a six-fold increase in the risk of recurrence in patients
who received topical steroids prior to transplantation(135).
CONCLUSION
There are many options of antifungal agents and routes of
administration, and the choice depends on both the aetiologic
agent and the location and extent of the infection (Table 1).
Standard therapy with polyenes remains effective. Despite
the numerous reports of infections that do not respond to first-
line drugs and improve after the introduction of other agents,
particularly second-generation triazoles, comparative studies
demonstrating the superiority of the latter are lacking.
Until the real benefit of the new generation of antifungal
agents is demonstrated, we believe such drugs should be used as
an alternative to standard therapy (Figure 1).
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